Johnson & Johnson Innovation’s William Hait talks about how the company is aiming to change the trajectory of human health through new approaches to R&D
IDEA Pharma on identifying as many paths to market as possible around phase 2, and not getting stuck on a ‘conveyor belt’ to inadequate phase 3 trial results
Sign up to receive complimentary editions of the magazine direct to your inbox, including the forthcoming Access and Commercialisation issue, which will also look at digital health and customer experience
Strength in numbers: Because having a rare disease isn’t rare
Global Genes’ Nicole Boice about why rare diseases need to be a global priority, and why she hopes her own organisation is heading towards obsolescence